Summary of the report market performanceAsiafifaworldcupqualifiers2022: may 13, 2024Asiafifaworldcupqualifiers2022The rise and fall of the pharmaceutical sector-0Asiafifaworldcupqualifiers2022.72%, outperforming the CSI 300 Index 0Asiafifaworldcupqualifiers2022.68pct, ranking 16th among 31 sub-industries. Among the pharmaceutical sub-industries, offline pharmacies (+ 1.30%), medical equipment (+ 0.32%) and medical R & D outsourcing (+ 0.18%) were the top performers, followed by in vitro diagnosis (- 2.31%), other biological products (- 2.10%) and vaccines (- 1.95%). In terms of individual stocks, the top three daily gains were Xintiandi (+ 19.97%), Fuxiang Pharmaceutical (+ 10.32%) and Shuangcheng Pharmaceutical (+ 10.09%). The top three declines were Dongbao Biology (- 10.72%), Tonghua Jinma (- 10.02%) and Kang Hui Pharmaceutical (- 9.96%). Industry news: Boehringer Ingelheim recently released positive data for the phase 1max phase 2a clinical study of innovative therapy BI 764524, HORNBILL. This study is the first to explore treatment options for diabetic macular ischemia (DMI). The study found that BI 764524 was well tolerated after single and multiple vitreous administration, reached its main safety end point, and showed early signs of potential efficacy. (source: Boehringer Ingelheim) Company News: Shanghai Pharmaceutical (601607): the company announced that the "I031 tablets" independently developed by the company received the "Drug Clinical trial approval notice" approved and issued by the State Drug Administration. Agree to carry out clinical trials of this product, the drug is a small molecule inhibitor, can inhibit tumor proliferation. Xinhua Medical (600587): the company announced that it recently received the "Registration Certificate of Medical Devices of the people's Republic of China" issued by the Drug Administration of Shandong Province, which is a dental pneumatic motor mobile phone. The scope of application is to use compressed air to drive the mobile phone to rotate, clamp dental low-speed needles for drilling, grinding and cutting treatment. Puli Pharmaceutical (300630): the company announced that it recently received a drug registration certificate for vancomycin hydrochloride for injection issued by the State Drug Administration. This product is suitable for infections caused by methicillin-resistant Staphylococcus aureus and other bacteria. East China Pharmaceutical (000963): the company announced that its subsidiary, Zhongmei Huadong, received an "acceptance notice" issued by the State Drug Administration (NMPA). The application for listing license of mehuatinib tablets for first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) adult patients with L858R replacement mutation in exon EGFR21 was accepted. Risk tips: new drug research and development and listing are not as expected; policy promotion is higher than expected; market competition aggravates the risk. [disclaimer] this article only represents the views of a third party and does not represent the position of Hexun. Investors operate accordingly, at their own risk.
[disclaimer] this article only represents the views of a third party and does not represent the position of Hexun. Investors operate accordingly, at their own risk.